vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
July 15 2019 - 4:59PM
Business Wire
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of orally administered treatments for Alzheimer’s disease and
diabetes, today announced that it will make an oral presentation at
the 2019 Alzheimer's Association International Conference (AAIC)
held in Los Angeles, California, July 14 – 18, 2019.
The presentation will highlight data from the phase 3 STEADFAST
Study and preceding phase 2b study of azeliragon to further support
the biological hypothesis for the potential beneficial effects of
azeliragon on the ADAS-cog and CDR-sb in patients with mild
Alzheimer’s disease and type 2 diabetes.
Details of the presentation are below:
Presentation Title: Linking Diabetes and Alzheimer’s
Disease through RAGE. A Retrospective Analysis of Azeliragon Phase
2 and Phase 3 Studies Session: O4-11 Clinical:
Prevention (clinical) and Human Trials - Inflammation Date and
Time: Wednesday, July 17, 2019, 5:00 – 5:15 pm PT
Location: Concourse Hall 152
The presentation slides will be made available on the
Publications page of the Company website.
About Azeliragon
Azeliragon, also known as TTP488, is an orally active
small-molecule antagonist of the receptor for advanced glycation
endproducts, RAGE. vTv Therapeutics discovered and developed
azeliragon using its proprietary drug discovery platform, TTP
Translational Technology®. A broad range of human pathologic and
experimental biologic investigation suggests that RAGE ligand
interactions lead to sustained inflammatory states that play a role
in chronic diseases such as diabetes, inflammation, and Alzheimer’s
disease. vTv is screening patients for a phase 2, randomized,
double-blind, placebo-controlled 6-month proof of concept study
evaluating azeliragon in patients with mild Alzheimer’s disease and
type 2 diabetes.
About vTv Therapeutics
vTv Therapeutics Inc. is a public, clinical-stage
biopharmaceutical company engaged in the discovery and development
of orally administered small molecule drug candidates to fill
significant unmet medical needs. vTv has a pipeline of clinical
drug candidates led by programs for the treatment of diabetes,
Alzheimer’s disease, and inflammatory disorders.
Forward-Looking Statements
This release contains forward-looking statements, which involve
risks and uncertainties. These forward-looking statements can be
identified by the use of forward-looking terminology, including the
terms “anticipate,” “believe,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and, in each case, their
negative or other various or comparable terminology. All statements
other than statements of historical facts contained in this
release, including statements regarding the timing of our clinical
trials, our strategy, future operations, future financial position,
future revenue, projected costs, prospects, plans, objectives of
management and expected market growth are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Important factors that
could cause our results to vary from expectations include those
described under the heading “Risk Factors” in our Annual Report on
Form 10-K and our other filings with the SEC. These forward-looking
statements reflect our views with respect to future events as of
the date of this release and are based on assumptions and subject
to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These
forward-looking statements represent our estimates and assumptions
only as of the date of this release and, except as required by law,
we undertake no obligation to update or review publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise after the date of this release. We
anticipate that subsequent events and developments will cause our
views to change. Our forward-looking statements do not reflect the
potential impact of any future acquisitions, merger, dispositions,
joint ventures or investments we may undertake. We qualify all of
our forward-looking statements by these cautionary statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190715005803/en/
Investors: vTv Therapeutics Inc. IR@vtvtherapeutics.com or
Media: Josh Vlasto 212-572-5969 PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024